Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334839 | 0.94 | GLP1R (0.31) | CYP11B1CYP11B2 | |
| SCHEMBL2492764 | 0.80 | HTT (0.33) | CYP11B1CYP11B2SLC22A12 | |
| SCHEMBL5021673 | 0.76 | CHRNB2 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL20489642 | 0.75 | ALDH1A1 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL18760421 | 0.71 | ALDH1A1 (0.41) | — | |
| SCHEMBL335593 | 0.69 | CHRNB2 (0.38) | CYP11B1CYP11B2 | |
| SCHEMBL10179290 | 0.68 | EGLN1 (0.41) | — | |
| SCHEMBL17512472 | 0.68 | THRB (0.38) | SLC22A12 | |
| SCHEMBL17173719 | 0.68 | CCR1 (0.34) | — | |
| SCHEMBL990259 | 0.67 | PLAU (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2300476-B1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2014-01-08 | — | — | EP | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| US-8097628-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-01-17 | — | — | US | disclosed |
| WO-2010081874-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| US-20090306089-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141398-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | NAT1, RIF1, MRPL21 | CYP11B1 1547/4885CYP11B2 1301/4885SLC22A12 3990/4885 |
| US-20090306089-A1 | COMPOUNDS | SDHA, NQO1, SDHB | CYP11B1 7/4885CYP11B2 4/4885SLC22A12 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.